Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ZEALBullishCorporate Developmentsnews

Medium materiality6/10

Zealand Pharma reports week 36 share buy-back progress; potential EPS impact

Sep 7, 2026, 11:29 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The buy-back reduces share count, can elevate EPS, and often provides price support in the near term; progress toward the cap and the 5.47% treasury stake indicate ongoing capital discipline, which historically supports small- to mid-cap stocks if cash is deployable without impairing operations.

AI summary

What happened, with direct paths to the underlying reporting

Zealand Pharma disclosed week-36 buy-back activity under its MAR-compliant program. It purchased 183,000 shares in week 36, bringing accumulated buys to 3,046,000 shares (about 5.47% of share capital) with a total program value of 924.48 million DKK. The plan runs through October 31, 2026, capping at 1.3 billion DKK, with Danske Bank as lead manager.

ZEAL reports week 36 share buy-back transactions under MAR.
Program cap up to 1.3B DKK with a max of 7,152,557 shares.
Week 36 adds 183,000 shares; accumulated 3,046,000 under the program.
Program runs through Oct 31, 2026; Danske Bank is lead manager.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Zealand Pharma reports week 36 share buy-back progress; potential EPS impact

Zealand Phase 2 petrelintide data strengthens obesity therapy outlook

Roche takes big step in weight-loss field with $5.3 billion deal. Novo Nordisk shares fall. - MarketWatch

Zealand Pharma Shares Jump 17% After Positive Trial Results For Ozempic Competitor